The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Combined irinotecan and cisplatin therapy for extrapulmonary small cell carcinoma (EPSCC).
K. Nakano
No relevant relationships to disclose
T. Yuasa
No relevant relationships to disclose
N. Nishimura
No relevant relationships to disclose
Y. Mishima
No relevant relationships to disclose
S. Sakajiri
No relevant relationships to disclose
M. Yokoyama
No relevant relationships to disclose
S. Takahashi
No relevant relationships to disclose
K. Hatake
No relevant relationships to disclose